CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, today announced that it has entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next-generation bioconjugates..

马萨诸塞州剑桥市，2023年11月13日/PRNewswire/-Nona Biosciences是技术创新和抗体发现与开发解决方案的全球先驱，今天宣布已与GeneQuantum Healthcare进行战略合作，以促进早期发现下一代生物共轭物。。

Under the terms of the collaboration, Nona Biosciences will integrate GeneQuantum's exclusive and innovative iLDC (intelligent Ligase-dependent Conjugation) and iGDC (intelligent Glycotransferase-dependent conjugation) platforms, with Nona Biosciences' Harbour Mice® platform and cutting-edge technologies, to further enhance technology platform capabilities, providing global partners with a one-stop solution for the early discovery of next-generation bioconjugates..

根据合作条款，Nona Biosciences将整合GeneQuantum专有和创新的iLDC（智能连接酶依赖性结合）和iGDC（智能糖转移酶依赖性结合）平台，以及Nona Biosciences的Harbour Mice®平台和尖端技术，以进一步增强技术平台功能，为全球合作伙伴提供一站式解决方案，以便早期发现下一代生物共轭物。。

'Leveraging our cutting-edge antibody technologies and extensive experience in antibody research and development, Nona is committed to providing innovative, diverse and customized solutions for preclinical drug development. These efforts have garnered widespread recognition and appreciation from our partners,' said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, 'We look forward to collaborating with GeneQuantum Healthcare to continuously enhance the capabilities of innovative bioconjugate drug research and development, empowering global partners to advance their ADC drug R&D initiatives.'.

“利用我们尖端的抗体技术和抗体研究与开发方面的丰富经验，Nona致力于为临床前药物开发提供创新，多样化和定制的解决方案。这些努力得到了我们合作伙伴的广泛认可和赞赏，“我们期待与GeneQuantum Healthcare合作，不断增强创新性生物共轭药物研究与开发的能力，增强全球能力。”合作伙伴推进其ADC药物研发计划“。

'Through years of interdisciplinary and differentiated innovation, GeneQuantum has developed iLDC and iGDC platforms as the core technology for bioconjugate drugs, offering a comprehensive solution for ADC drug R&D and manufacture. Overcoming the challenges prevalent in the current ADC field, such as heterogeneity, poor stability, process complexity, difficulty in scale-up manufacture, these leading technologies significantly reduce the production cost, improve the drug quality, and increase the ADC  drug global accessibility.' said Gang Qin, PhD, Founder and Chairman of GeneQuantum Healthcare, 'We are honored to enter a strategic collaboration with Nona Bioscience on early screening and discovery of bioconjugate drugs.

“通过多年的跨学科和差异化创新，GeneQuantum开发了iLDC和iGDC平台作为生物共轭药物的核心技术，为ADC药物研发和制造提供了全面的解决方案。克服当前ADC领域普遍存在的挑战，如异质性，稳定性差，工艺复杂，难以扩大规模生产，这些领先技术显着降低了生产成本，提高了药品质量，并提高了ADC药物的全球可及性。'GeneQuantum Healthcare的创始人兼主席Gang Qin博士说：“我们很荣幸与Nona Bioscience在早期筛选和发现生物共轭药物方面开展战略合作。

By leveraging GeneQuantum's conjugation technology and Nona's extensive drug development experience, we believe that this collaboration will substantially improve high-quality and high-throughput screening for the early discovery of ADC drugs.'.

通过利用GeneQuantum的结合技术和Nona广泛的药物开发经验，我们相信这项合作将大大改善早期发现ADC药物的高质量和高通量筛选。

About Nona Biosciences

诺纳生物科学

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) is a global biotechnology company committed to cutting-edge technology innovation and provides a total solution from 'Idea to IND' (I to ITM), ranging from target validation and antibody discovery through preclinical research.

Nona Biosciences（HBM Holdings Limited的合资子公司，HKEX:02142）是一家致力于尖端技术创新的全球生物技术公司，提供从“创意到IND”（I到ITM）的全面解决方案，范围从目标验证和通过临床前研究发现抗体。

The integrated antibody discovery services range from antigen preparation, animal immunization, highly robust antibody screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® technology and the experienced therapeutic antibody discovery team..

综合抗体发现服务包括抗原制备，动物免疫，高度稳健的抗体筛选，抗体铅生成和工程，可开发性评估和药理学评估，利用Harbour Mice®技术和经验丰富的治疗性抗体发现团队的优势。。

Harbour Mice® generate fully human monoclonal antibodies in a traditional two heavy and two light chain (H2L2) format, and a heavy chain only (HCAb) format. Integrating Harbour Mice® with highly robust antibody screening platforms, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs..

Harbour Mice®产生传统的双重链和双轻链（H2L2）形式的完全人单克隆抗体，以及仅重链（HCAb）形式。将Harbour-Mice®与高度强大的抗体筛选平台相结合，Nona Biosciences专注于推动全球变革性下一代药物的发明。。

For more information, please visit: www.nonabio.com

欲了解更多信息，请访问：www.nonabio.com

About GeneQuantum Healthcare

关于GeneQuantum医疗保健

GeneQuantum Healthcare (Suzhou) Co., Ltd. is an innovative high-tech company dedicated to the development of novel First-in-Class and Best-in-Class biological drugs, the pioneer in leveraging enzymatic site-specific conjugation technology to develop ADC drugs. GeneQuantum has established a complete and underlying technology system iLDC® and iGDC®, which can deliver a whole process solution for various conjugated drugs from molecular design to commercial production.

GeneQuantum Healthcare（苏州）有限公司是一家创新型高科技公司，致力于开发新型一流和一流的生物药物，是利用酶促位点特异性结合技术开发ADC药物的先驱。GeneQuantum已经建立了一个完整的基础技术系统iLDC®和iGDC®，可以为从分子设计到商业生产的各种共轭药物提供全过程解决方案。

Multiple innovative and clinical ADC varieties have been successfully developed based on this technology platform. ADCs developed with GeneQuantum's conjugation technology have iterative advantages in process quality and metabolic stability. Moreover, the seamless integration between intelligent conjugation process and antibody process greatly reduces the overall commercial production cost.

基于该技术平台，已成功开发出多种创新和临床ADC品种。用GeneQuantum共轭技术开发的ADC在过程质量和代谢稳定性方面具有迭代优势。此外，智能共轭过程与抗体过程的无缝整合大大降低了整体商业生产成本。

GeneQuantum is committed to 'enabling' the development of various bioconjugate drugs in the world and establishing industry ecosystem and win-win cooperation. Please visit for more information: https://www.genequantum.com..

GeneQuantum致力于“推动”世界各种生物共轭药物的开发，建立产业生态系统和互利合作。请访问以获取更多信息：https://www.genequantum.com..

SOURCE Nona Biosciences

SOURCE诺纳生物科学